Systems and methods for measuring cell signaling protein activity
US-2024230643-A9 · Jul 11, 2024 · US
Compositions and methods of using chondroitinase ABCI mutants
US9102930B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102930-B2 |
| Application number | US-201313849420-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 22, 2013 |
| Priority date | Oct 10, 2006 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated nucleic acid sequence comprising a nucleotide sequence selected from SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 14, encoding a mutant chondroitinase ABCI enzyme. 2. The isolated nucleic acid sequence of claim 1 , wherein the nucleic acid sequence encodes a mutant chondroitinase ABCI enzyme selected from SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 6. 3. The isolated nucleic acid sequence of claim 1 , where…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9102930B2 cover?
- The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
- Who is the assignee on this patent?
- Acorda Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/88. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).